Original article. Introduction
|
|
- Juniper O’Connor’
- 5 years ago
- Views:
Transcription
1 Original article Annals of Oncology 15: , 2004 DOI: /annonc/mdh026 Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study K. Zervas, M. A. Dimopoulos*, E. Hatzicharissi, A. Anagnostopoulos, M. Papaioannou, Ch. Mitsouli, P. Panagiotidis, J. Korantzis, M. Tzilianos & A. Maniatis On behalf of the Greek Myeloma Study Group Greek Myeloma Study Group, Athens, Greece Received 9 June 2003; revised 9 September 2003; accepted 17 September 2003 Introduction Background: High-dose chemotherapy with autologous stem cell transplantation after initial cytoreductive chemotherapy with the combination vincristine, doxorubicin and dexamethasone (VAD) is considered an effective therapy for many patients with newly diagnosed, symptomatic multiple myeloma. Response to initial cytoreductive chemotherapy is important for the long-term outcome of such patients. Thalidomide has recently shown significant antimyeloma activity. We studied the efficacy and toxicity of the combination of a liposomal doxorubicin-containing VAD regimen with thalidomide, administered on an outpatient basis, as initial cytoreductive treatment in previously untreated patients with symptomatic myeloma. Patients and methods: Thirty-nine myeloma patients were treated with vincristine 2 mg intravenously (i.v.), liposomal doxorubicin 40 mg/m 2 i.v. administered as single dose on day 1, and dexamethasone 40 mg per os daily for 4 days. Dexamethasone was also given on days of the first cycle of treatment. The regimen was administered every 4 weeks for four courses. Thalidomide was given daily at a dose of 200 mg at bedtime. Response to treatment was evaluated after four cycles of treatment. After completion of four cycles, the patients were allowed to proceed to high-dose chemotherapy or to receive two additional cycles of the same treatment. Results: On an intention-to-treat basis, 29 of the 39 patients (74%) responded to treatment. Four patients (10%) achieved complete and 25 (64%) partial response. Three patients (8%) showed minor response and seven (18%) were rated as non-responders. Major grade 3 or 4 toxicities consisted of neutropenia (15%), thrombocytopenia (15%), deep vein thrombosis (10%), constipation (10%), skin rash (5%) and peripheral neuropathy (5%). Two patients (5%) experienced early death due to infection. Conclusions: The combination of vincristine, liposomal doxorubicin, and dexamethasone (VAD doxil) with thalidomide is an effective and relatively well-tolerated initial cytoreductive treatment.prospective randomized studies are required in order to assess the effect of this regimen on the long-term outcome of patients with multiple myeloma. Key words: liposomal doxorubicin, multiple myeloma, thalidomide *Correspondence to: M. A. Dimopoulos, 227 Kifissias Avenue, Kifissia, Athens 14561, Greece. Tel: ; Fax: ; mdimop@med.uoa.gr In multiple myeloma (MM) patients the 4-day continuous infusion of vincristine, doxorubicin and dexamethasone (VAD) is considered an effective initial treatment, especially if consolidation with high-dose chemotherapy and autologous stem cell rescue is planned. The VAD regimen induces early reduction of tumor burden and is less toxic to bone marrow stem cells than regimens that contain alkylating agents. The response rate after VAD ranges from 55 to 75% [1 3]. Increased cardiac toxicity and neurotoxicity due to doxorubicin and vincristine, respectively, may be limiting factors. In addition, the administration of VAD is cumbersome, requiring central venous access for continuous infusion of chemotherapy. Recent studies have shown that the administration of VAD on an outpatient basis using 4 days of rapid intravenous (i.v.) infusion (VAD bolus) or the substitution of pegylated liosomal doxorubicin for doxorubicin in the VAD regimen (VAD doxil) are equally active to standard infusional VAD [4 6]. Liposomal doxorubicin has a prolonged half-life compared to standard doxorubicin, thus allowing increased exposure of the myeloma cells to the former agent [7]. Furthermore, in myeloma patients there is increased angiogenic activity in the bone marrow [8]. This may allow for higher concentration of the pegylated form where the tumor is concentrated. Conventional chemotherapy followed by high-dose therapy and autologous stem cell transplantation is associated with improved 2004 European Society for Medical Oncology
2 135 survival compared to conventional chemotherapy alone [9, 10]. Furthermore, response to initial cytoreductive treatment has significant impact on the results of subsequent high-dose chemotherapy [11]. Thus, rapid and profound reduction of myeloma load may be advantageous for newly diagnosed patients who require treatment. Singhal et al. first reported that thalidomide induced objective responses in one-third of patients with refractory myeloma, most of whom had also received one or two high-dose therapies [12]. Thalidomide has multiple mechanisms of antimyeloma activity which may differ from those of conventional chemotherapy and of corticosteroids [13]. Furthermore, single-agent thalidomide is active in at least one-third of patients with newly diagnosed myeloma [14]. Thus, we designed a multicenter phase II study in order to assess the efficacy and tolerability of the combination of VAD doxil, with thalidomide as an outpatient treatment for newly diagnosed patients with multiple myeloma who require therapy. The major benefits for the patients using the VAD doxil regimen could be the avoidance of a central venous line and the reduction of days of hospitalization or outpatient visits. Patients and methods Eligibility Newly diagnosed patients with symptomatic myeloma and age 75 years were included in the study. Eligible patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status 3, life expectancy >3 months, left ventricular ejection fraction (LVEF) 50% and adequate liver function. Patients with renal failure not requiring hemodialysis were also eligible. All patients provided informed consent according to institutional guidelines. Study design This was a prospective multicenter phase II study with primary end point objective response rate (i.e. complete plus partial response) of the combination of VAD doxil with thalidomide (T-VAD doxil). Based on previous reports on the activity of VAD doxil and of thalidomide in previously untreated patients with multiple myeloma, we considered that an objective response rate of 70% ± 15% with a 95% confidence interval would be acceptable. Thus, 37 patients were required. All patients were scheduled to receive four courses of T-VAD doxil before final assessment of response. Subsequently, patients <70 years with responding disease were allowed to proceed to blood stem cell mobilization with intermediate dose cyclophosphamide (4 g/m 2 i.v.) followed by highdose melphalan (200 mg/m 2 i.v.) and autologous stem cell rescue, or to receive two additional cycles of T-VAD doxil with or without subsequent maintainance. The decision of high-dose therapy was left to the patient and his primary physician. Complete clinical and laboratory evaluation was performed in all patients before treatment, including X-ray skeletal survey, serum protein electrophoresis and 24-h urine protein quantitation and electrophoresis, immunofixation, determination of serum immunoglobulins, b 2 microglobulin (b 2 M) and C-reactive protein (CRP), LVEF, as well as bone marrow aspiration and biopsy. Baseline assessments, except X-ray skeletal survey, were repeated before each cycle of treatment. Bone marrow aspiration, biopsy and X-ray skeletal survey were repeated 4 weeks after administration of the fourth cycle of treatment. The monoclonal immunoglobulin response was assessed before each cycle of treatment for determination of time to response. Toxicity was also evaluated before each cycle of treatment. The National Cancer Institute common toxicity criteria (version 2) were used to grade adverse effects. Patients who discontinued treatment at any time because of death, toxicity or patient s refusal to continue were rated as non-responders. The event-free survival was estimated from the date of diagnosis to the date of disease progression or death from any cause. Overall survival was defined from the date of diagnosis to the date of death from any cause. Treatment and response criteria The VAD doxil regimen consisted of vincristine 2 mg in 100 ml NaCl 0.9% on day 1, liposomal doxorubicin 40 mg/m 2 in 500 ml DSW i.v. over 1 h on day 1 and dexamethasone 40 mg per os daily for 4 days. Dexamethasone was also given in the first cycle of treatment on days Thalidomide was given daily at bedtime and at a dose of 200 mg continuously. The regimen was administered every 4 weeks for four cycles and subsequently patients underwent final assessment. The response criteria used in this study were complete response (CR): disappearance of serum and/or urine monoclonal component (MC) in immunofixation, bone marrow plasma cells 5% with no evidence of clonality with immunohistochemistry; partial response (PR): 50% decrease of serum MC levels and/or 90% decrease of Bence Jones proteinouria, 50% decrease in transverse diameter of existing plasmacytomas; minor response (MR): 50% but 25% decrease of serum MC, improvement of performance status by one grade; stable disease (SD): no fulfilling criteria for CR, PR or PD; progressive disease (PD): 50% increase in serum and/or urine MC above the response level, 50% increase in transverse diameter of soft tissue plasmacytomas, progression of lytic bone lesions. Also, increase 25% but 50% of MC in conjunction of hypercalcemia (Ca >11mg/dl) or disease-related hemoglobin decrease of 2 g/dl was considered as PD. Criteria for CR and PR must persist in two evaluations 4 weeks apart. Results Patient characteristics Since March 2001, 39 previously untreated patients (20 males and 19 females), with a median age of 68 years (range years) were entered into the study. Patient characteristics are listed in Table 1. Eight of 39 patients had stage IIIB disease, 16 had serum b 2 microglobulin >4 mg/l, 14 had serum C-reactive protein >6 mg/l and 12 patients had serum albumin <3 g/dl. Response to therapy Overall, 29 of the 39 patients (74%) achieved a significant response. Four patients (10%) achieved CR and 25 (64%) PR. Three patients (8%) showed MR. Inclusion of these minor responses increases the overall response rate to 82%. The time to response was short and at least 50% reduction of monoclonal protein was noted within 2 months of treatment in 80% of responding patients. In all these patients the monoclonal protein response was confirmed by bone marrow examination after four cycles of treatment. Seven patients (18%) were characterized as non-responders. Six of them experienced early death during the first 3 months of treatment, due to disease progression (four patients) or neutropenic infection (two patients). Of the 32 patients who showed response after four cycles of treatment, 15 (47%) proceeded to blood stem cell collection and subsequent high-dose melphalan. The median number of apheresis was two (range one to three). The median number of CD34+ cells that were collected was cells/kg (range cells/kg). The remaining 17 patients
3 136 Table 1. Patient characteristics Characteristic No. of patients (%) Median age, years (range) 68 (43 75) Sex Male 20 (51) Female 19 (49) Stage (Durie Salmon system) II 14 (36) IIIA 17 (43.5) IIIB 8 (20.5) ECOG performance status (43.5) (56.5) Monoclonal protein IgG 22 (56.5) IgA 11 (28) Light chain only 5 (13) Non-secretory 1 (2.5) Serum b2 microglobulin, median (range) 3.9 mg/l ( ) Serum C-reactive protein, median (range) 3.0 mg/l (0.4 29) Serum albumin, median (range) 3.2 g/dl (2 4.5) Bone marrow plasma cells (%), median (range) 60 (20 90) ECOG, Eastern Cooperative Oncology Group; IgA, immunoglobulin A; IgG, immunoglobulin G. completed six cycles of treatment. Eleven of these patients (65%) continued with maintenance treatment with dexamethasone (40 mg per os 4 days every month) and six (35%) received no further treatment. Median follow-up was 10 months (range 2 22 months). During follow-up two patients, with initial partial response, progressed 15 and 19 months from diagnosis. Of the 39 patients, eight died (20.5%). Two responders died; one after disease progression and the other during autologous stem cell transplantation because of aspergillosis. Event-free survival and overall survival at 22 months were 55% and 74%, respectively (Figure 1). Toxicity Figure 1. Overall and event-free survival. Table 2. Grade 2 4 adverse events according to the National Cancer Institute Adverse event Patients (%) Grade 2 Grade >3 4 Treatment-related deaths 2 (5) Neutropenic infection 5 (13) Infection without neutropenia 4 (10) 3 (8) Constipation 26 (67) 4 (10) Somnolence 21 (54) Dizziness 16 (41) Tingling/numbness 18 (46) 1 (2.5) Tremor 13 (33) Edema 9 (23) Deep vein thrombosis 4 (10) Rash 5 (13) 2 (5) Palmar plantar erythrodysesthesia 4 (10) Mucositis 7 (18) 2 (5) Neutropenia 5 (13) 6 (15) Thrombocytopenia 4 (10) 6 (15) The most common toxicities recorded during the four cycles of treatment are shown in Table 2. Treatment was generally well tolerated and no patient discontinued therapy because of toxicity. Five patients developed neutropenic infections; in two patients these were associated with pneumonia and in three patients no focus of infection or positive culture was found. Two patients died within the first 2 months of treatment of infectious complications. Most patients experienced mild somnolence, constipation, dizziness and tremor. Grade 1 or 2 peripheral neuropathy was noted in 46% of patients, whereas one patient developed grade 3 neutropathic pain. Palmar plantar erythrodysesthesia, grade 2, was observed in four patients (10%). Four patients (10%) developed uncomplicated deep vein thrombosis (DVT) requiring anticoagulant therapy. Severe, grade 3, hematological toxicity was observed in six patients (15%). Discussion To the best of our knowledge we report the first completed study which combined thalidomide with a VAD-like regimen for the primary treatment of patients with multiple myeloma. The antimyeloma activity of thalidomide was first reported by Singhal et al. and subsequently several independent studies confirmed the activity of this agent in relapsed and refractory myeloma [12, 13, 15 18]. It appears that thalidomide has multiple mechanisms of action including inhibition of angiogenesis, downregulation of tumor necrosis factor, inhibition of myeloma cell adhesion to the
4 137 bone marrow stroma, and stimulation of natural killer cells and T-lymphocytes [19]. The combination of thalidomide with dexamethasone showed synergism in vitro [20] and demonstrated activity in at least 50% of patients with refractory multiple myeloma [21, 22]. Moreover, two recent studies assessed the efficacy of this combination in previously untreated patients and reported objective responses in 64% and 72% of patients, respectively, but patients with high tumor mass were excluded from the latter study [23, 24]. We have recently reported a prospective randomized trial for previously untreated patients with multiple myeloma and we observed that VAD doxil was active in 61% of patients. In our current study we added thalidomide to this regimen and we documented an objective response in 74% of patients, including complete responses in 10% of patients. These data appear encouraging since our study was conducted in several hospitals and since the median age of our patients was 68 years. The median time to response was rapid, consistent with previous experience with VAD-like regimens [2, 6]. Monoclonal protein response was associated with clearing of bone marrow plasmacytosis in all patients. Approximately one-half of the responding patients underwent blood stem cell collection in order to support the administration of high-dose i.v. melphalan. Despite the small number of patients there was no evidence that prior treatment with T-VAD doxil affected the collection of blood stem cells. A preliminary analysis from Cleveland Clinic indicated that the administration of T-VAD doxil to previously untreated patients induced objective responses in 88% of patients including complete responses in 24% [25]. Thalidomide was started at 50 mg/day and increased by 50 mg/day each week to a maximum tolerated dose up to 400 mg/day. This study was performed in a single institution and the median age of its patients was 7 years younger than that of our patients [25]. We used an intermediate dose of thalidomide at 200 mg per os daily despite the fact that we were aware that some studies have indicated that the cumulative 3-month dose of single-agent thalidomide in resistant patients is a prognostic factor for response [15, 17]. However, such a dose response effect has not been reported when thalidomide is combined with dexamethasone or with chemotherapy. Furthermore, in our phase II study we were concerned about the possibility of increased neurotoxicity with the combination of high-dose thalidomide and vincristine. However, it is possible that a higher dose of thalidomide might have increased the response rate of our T-VAD regimen. The combination of thalidomide and VAD doxil was relatively well tolerated. Two patients died due to infectious complications and five developed neutropenic infections necessitating hospitalization and i.v. antibiotics. Primary treatment with thalidomide and dexamethasone has also induced treatment-related deaths in 5% and in 6% of patients, respectively [23, 24]. A recent report with a regimen similar to our T-VAD doxil regimen indicated that with prophylactic amoxycillin 250 mg twice daily, acyclovir 400 mg twice daily and granulocyte colony-stimulating factor for white blood cell counts <5000/ml, there was reduction of infectious episodes [25]. Side-effects due to thalidomide, such as constipation, somnolence, tremor edema and skin rash, occurred in several of our patients. The incidence of palmar plantar erythrodysesthesia associated with liposomal doxorubicin was relatively low, probably due to the concomitant administration of dexamethasone. Nevertheless, grade 3 and 4 skin toxicity, neuropathy and constipation were rarely seen in this study, probably as a result of the short duration of treatment, for most of the patients, and because of the lower dose of thalidomide used in our study. There are data showing that the combination of thalidomide with doxorubicincontaining chemotherapy is associated with an increased risk of DVT, especially in newly diagnosed patients [26, 27]. Recent in vitro data suggest that thalidomide may be procoagulant through stimulation of thrombin receptors of doxorubicin-injured endothelium [28]. Higher incidence of DVT was also reported when the combination of thalidomide and dexamethasone was administered to previously untreated patients [23, 24]. In our study, 10% of the patients developed DVT which is similar to that reported with combination of thalidomide and dexamethasone. Compared to the incidence reported with the combination of thalidomide and doxorubicin-containing chemotherapy, the incidence of DVT in our study appeared lower. This difference could be attributed to the low dose of thalidomide and/or to the liposomal formulation of doxorubicin that we used. Nevertheless, the number of patients in our study is too small to draw any definitive conclusions regarding the incidence of DVT. This complication remains an important issue when thalidomide is combined with chemotherapy in previously untreated patients. The optimal prophylaxis for DVT after thalidomide has not been clearly established [13]. The benefits of anticoagulant therapy should be balanced against the risks. Until then we advocate prophylactic treatment either with low molecular weight heparin or with coumadin for newly diagnosed patients treated with T-VAD doxil. From our study, no conclusions can be drawn regarding time to progression and overall survival, since we treated a mixture of younger patients who could undergo autologous stem cell transplantation (ASCT) after induction treatment with T-VAD doxil and of older patients who continued the same treatment. The interest of T-VAD doxil is different in the two populations. In younger patients the main interest is to obtain a more profound tumor burden reduction prior to ASCT without reducing the hematopoietic quality of the graft. In older patients the main goals are to increase response rate and time to progression. We conclude that the combination of thalidomide with VAD doxil may represent an effective cytoreductive regimen for previously untreated patients with multiple myeloma. In order to fully assess the impact of thalidomide on the activity of VAD doxil we are currently conducting a prospective randomized trial, which compares VAD doxil with or without thalidomide. Acknowledgements We are grateful to Asimina Petropoulou for editing and typing the manuscript. References 1. Samson D, Newland A, Kearney J et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; ii:
5 Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: Abrahamson GM, Bird JM, Newland AC et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 1996; 94: Segeren CM, Sonneveld P, van der Holt B et al. Vicristine doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: Hussein MA, Wood L, Hsi E et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95: Dimopoulos MA, Pouli A, Zervas K et al. Prospective randomized comparison of VAD administered as intravenous bolus injection and VAD with liposomal doxorubicin as first line treatment in multiple myeloma. Ann Oncol 2003; 14: Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: Bjorkstrand B. European group for Blood and Marrow Transplantation registry studies in multiple myeloma. Sem Hematol 2001; 38: Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: Cavenagh JP, Oakervee H. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: Rajkumar V, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early stage myeloma. Leukemia 2003; 17: Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: Yakoub-Agha I, Attal M, Dumont et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients report of the Intergroup Francophone due Myelome (IFM). Hematol J 2002; 3: Neben K, Moehler T, Benner A et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: Tosi P, Zamagni E, Cellin C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003; 120: Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: Palumbo A, Giaccone L, Bringhen S et al. Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. Blood 2001; 98: 162a. 23. Rajkumar VS, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: Weber D, Rankin K, Cavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: Hussein MA. Doxil, vincristine, decadron and thalidomide (DVD-T) for newly diagnosed, and relapsed/refractory multiple myeloma; response to therapy and supportive care issues. Hematol J 2003; 4 (Suppl 1): S Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: Osman K, Comenzo R, Rajkumar SV. Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: Kaushal V, Kaushal GP, Mlekaveri S et al. Thalidomide protects endothelial cells from doxorubicin-induced injury but alters cell morphology. Hematol J 2003; 4 (Suppl 1): S248.
original article introduction original article
Annals of Oncology 18: 1369 1375, 2007 doi:10.1093/annonc/mdm178 VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the
More informationOriginal article. Introduction
Original article Annals of Oncology 14: 1039 1044, 2003 DOI: 10.1093/annonc/mdg287 Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus
More information37 Novel Therapies for
37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different
More informationWALDENSTROM S macroglobulinemia (WM) is a
Treatment of Waldenstrom s Macroglobulinemia With Thalidomide By Meletios A. Dimopoulos, Athanassios Zomas, Nora A. Viniou, Vassiliki Grigoraki, Eleni Galani, Charis Matsouka, Olga Economou, Nikolaos Anagnostopoulos,
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationD.J. White MD MSc,* N. Paul PhD, D.A. Macdonald MD,* R.M. Meyer MD, and L.E. Shepherd MD ORIGINAL ARTICLE ABSTRACT KEY WORDS 1.
ORIGINAL ARTICLE Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial D.J. White MD MSc,*
More informationBortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
VOLUME 45 ㆍ NUMBER 3 ㆍ September 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma Se
More informationTherapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 977-982, 2013 Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients CHENGCHENG FU, JUAN WANG, XUE XIN, HUI LIU,
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationMYBORPRE. Protocol Code. Lymphoma, Leukemia/BMT. Tumour Group. Dr. Kevin Song. Contact Physician
BC Cancer Protocol Summary for the Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant Protocol Code Tumour Group Contact
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationCitation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationUse of simple hematological, biochemical and clinical parameters to monitor response of multiple myeloma patients on high dose thalidomide therapy
Original Article Use of simple hematological, biochemical and clinical parameters to monitor response of multiple myeloma patients on high dose thalidomide therapy Uppal G, Raina V*, Sharma A*, Anand M**,
More informationClinical Study Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
Hindawi Publishing Corporation Stem Cells International Volume 2012, Article ID 607260, 6 pages doi:10.1155/2012/607260 Clinical Study Induction Therapy and Stem Cell Mobilization in Patients with Newly
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationKEY WORDS: Multiple myeloma, Complete remission, Prognostic factor, Overall survival, Autologous stem cell transplantation
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation Jin Seok Kim,
More informationManagement Update: Multiple Myeloma. Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College
Management Update: Multiple Myeloma Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College Introduction Multiple myeloma - clonal plasma cell neoplasm Monoclonal antibody
More informationSecond Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda, 1 Joseph Mikhael, 2 Andrew Winter, 1 Norman
More informationUpdates in the Treatment of Newly Diagnosed Multiple Myeloma: Combination Therapy with Bortezomib, Pegylated
Updates in the Treatment of Newly Diagnosed Multiple Myeloma: Combination Therapy with Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone The Practicing Oncologist s Perspective Interviews
More informationAHFS Final. Criteria Used in. Strength. Grade of. hydrochloride. per day on 12, and mg/m 2 IV. Strength. Grade of. Bortezomib 1.
AHFS Final Determination of Medical Acceptance: Off-label Use of Bortezomib in Combination with Doxorubicin and Dexamethasone as Inductionn Therapy for Newly Diagnosed Multiple Myeloma in Transplant-eligible
More informationJunru Liu*, Juan Li*, Beihui Huang, Dong Zheng, Mei Chen, Zhenhai Zhou, Duorong Xu, Waiyi Zou
Original Article Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma Junru Liu*, Juan
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationShigeki Ito, Tatsuo Oyake, Kazunori Murai, and Yoji Ishida. Correspondence should be addressed to Shigeki Ito;
Case Reports in Hematology Volume 213, Article ID 65192, 5 pages http://dx.doi.org/1.1155/213/65192 Case Report Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with
More informationArsenic Trioxide: An Emerging Therapy for Multiple Myeloma
Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma NIKHIL C. MUNSHI University of Arkansas for Medical Science, Little Rock, Arkansas, USA Key Words. Arsenic trioxide Multiple myeloma Antiangiogenesis
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationThalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield
(2007) 21, 1294 1299 & 2007 Nature Publishing Group All rights reserved 0887-6924/07 $30.00 www.nature.com/leu ORIGINAL ARTICLE Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationMedical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012
Medical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012 Support AL Amyloidosis (Light Chain Amyloidosis) Effective Date: 01/01/2013 Document: ARB0413:01 Revision Date: 10/24/2012 Code(s):
More informationScottish Medicines Consortium
Scottish Medicines Consortium lenalidomide, 5mg,10mg,15mg and 25mg capsules (Revlimid) No. (441/08) Celgene Europe Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment of
More informationMYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose
I have no conflicts of interest to disclose MYE FORMS REVEALED Janet Brunner, PA-C CIBMTR MKE New10_1.ppt OBJECTIVES 1) Be able to describe the criteria required for each myeloma response code 2) Be able
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationBortezomib (Velcade)
Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
ClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Tomer Mark 1, Angelique Boyer 1, Adriana Rossi 1, Manan Shah 1, Roger Pearse 1, Faiza Zafar
More informationPrognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
(2004) 34, 235 239 & 2004 Nature Publishing Group All rights reserved 0268-3369/04 $30.00 www.nature.com/bmt Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose
More informationRecent Advances in the Use of Lenalidomide for the Treatment of Multiple Myeloma
M a r c h 2 0 0 8 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 6, I s s u e 3, S u p p l e m e n t 7 Recent Advances in the Use of Lenalidomide for the Treatment of Multiple Myeloma A Review
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationASBMT. Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Biol Blood Marrow Transplant 19 (2013) 445e449 Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma Emilie Lemieux 1,y, Cyrille Hulin 2,y, Denis Caillot 3, Stéphanie Tardy
More informationThalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
The new england journal of medicine original article and Hematopoietic-Cell Transplantation for Multiple Myeloma Bart Barlogie, M.D., Ph.D., Guido Tricot, M.D., Ph.D., Elias Anaissie, M.D., John Shaughnessy,
More informationReview of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM
Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving
More informationBortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
Original Article Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment Guangzhong Yang, Wenming Chen, Yin Wu Department
More informationNew Drugs for Myeloma. Key Words. Bortezomib Lenalidomide Multiple myeloma Thalidomide
The Oncologist Myelomas New Drugs for Myeloma PAUL G. RICHARDSON, CONSTANTINE MITSIADES, ROBERT SCHLOSSMAN, NIKHIL MUNSHI, KENNETH ANDERSON Dana-Farber Cancer Institute, Harvard Medical School, Boston,
More informationKEY WORDS: Multiple myeloma, Autologous transplantation, Induction therapy
Short Course Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma Cristina
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationMajor Diagnostic Criteria
Multiple Myeloma Elizabeth Ann Coleman, PhD, RNP, AOCN Professor and Chair, Dept. of Nursing Science Cooper Chair in Oncology Nursing, College of Nursing Professor, Dept. of Internal Medicine, College
More informationP53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse
Blood First Edition Paper, prepublished online August 31, 2004; DOI 10.1182/blood-2004-04-1363 P53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse Prognostic Factor for Patients
More informationKR Desikan, G Tricot, M Dhodapkar, A Fassas, D Siegel, DH Vesole, S Jagannath, S Singhal, J Mehta, D Spoon, E Anaissie, B Barlogie and N Munshi
(2000) 25, 483 487 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning
More informationAutologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation
() 25, 723 728 Macmillan Publishers Ltd All rights reserved 268 3369/ $15. www.nature.com/bmt Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationJ Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION
VOLUME 27 NUMBER 3 OCTOBER 2 29 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationAge 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant
Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant Parneet K. Cheema, Sahar Zadeh, Vishal Kukreti, Donna Reece,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationMyeloma care and proteasome inhibitors. Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania
Myeloma care and proteasome inhibitors Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania Why care about CV toxicities in MM? Median age 72 years About 2/3 have CV disease at baseline
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationAdvances in biology and treatment of multiple myeloma
Annals of Oncology 16 (Supplement 2): ii106 ii112, 2005 doi:10.1093/annonc/mdi717 Advances in biology and treatment of multiple myeloma H. Ludwig Wilhelminenspital, Vienna, Austria Biology A multistep
More informationBackground Information
What is Velcade (bortezomib)? Velcade (bortezomib) is a medicine used to treat a blood cancer known as multiple myeloma, and was the first of the treatments in the class of anti-cancer drugs known as proteasome
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationPlasma Cell Disorders (PCD) Pre-HCT Data
Plasma Cell Disorders (PCD) Pre-HCT Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: HCT type: (check
More information& 2004 Nature Publishing Group All rights reserved /04 $
(2004) 33, 381 388 & 2004 Nature Publishing Group All rights reserved 0268-3369/04 $25.00 www.nature.com/bmt Amyloidosis High-dose intravenous melphalan and autologous stem cell transplantation as initial
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationSerum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial
Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Jill Corre*, Thomas Dejoie, Helene Caillon, Michel Attal*,
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationSeok Jin Kim 1,, Kihyun Kim 1,, Young Rok Do 2, Sung Hwa Bae 3, Deok-Hwan Yang 4 and Je-Jung Lee 4,* INTRODUCTION
Jpn J Clin Oncol 2011;41(3)353 357 doi:10.1093/jjco/hyq194 Advance Access Publication 14 October 2010 Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib:
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationSurvival and prognostic factors after initiation of treatment in Waldenstrom s macroglobulinemia
Original article Annals of Oncology 14: 1299 1305, 2003 DOI: 10.1093/annonc/mdg334 Survival and prognostic factors after initiation of treatment in Waldenstrom s macroglobulinemia M. A. Dimopoulos*, G.
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationForms Revision: Myeloma Changes
Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.
More informationKeywords: multiple myeloma; autologous; allogeneic stem cell transplantation. Summary:
Bone Marrow Transplantation, (1999) 23, 317 322 1999 Stockton Press All rights reserved 268 3369/99 $12. http://www.stockton-press.co.uk/bmt Induction therapy with vincristine, adriamycin, dexamethasone
More informationMultiple Myeloma in the Elderly: When to Treat, When to Go to Transplant
Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Review Article [1] October 15, 2010 By Jean-luc Harousseau, MD [2] Until recently, standard treatment of multiple myeloma (MM) in
More informationSession Chair: Philip R. Greipp, MD Speakers: Robert Z. Orlowski, MD, PhD; Jeffrey A. Zonder, MD; and Bhoomi Mehrotra, MD
Multiple Myeloma Session Chair: Philip R. Greipp, MD Speakers: Robert Z. Orlowski, MD, PhD; Jeffrey A. Zonder, MD; and Bhoomi Mehrotra, MD Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates
More informationMultiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015
Multiple Myeloma: diagnosis and prognostic factors N Meuleman May 2015 Diagnosis Diagnostic assessment of myeloma: what should we know? Is it really a myeloma? Is there a need for treatment? What is the
More informationBiology of Blood and Marrow Transplantation 12: (2006) 2006 American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 12:837-844 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1208-0006$32.00/0 doi:10.1016/j.bbmt.2006.04.006 New Staging Systems
More informationSuccessful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy
CASE REPORT Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy Naohiro Sekiguchi 1, Naoki Takezako 1, Akihisa Nagata 1, Miyuki Wagatsuma 2, Satoshi Noto 1, Kazuaki
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationTracking Disease Status for Multiple Myeloma
Tracking Disease Status for Multiple Myeloma This appendix is intended to provide additional resources when determining: Best response to line of therapy pre-transplant; Disease Status at the Last Evaluation
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationVAD. ALT TP Glb Ca CT MRI. . mg/dl X X A CT VAD VAD. GdhDTPA T.
VAD h h h hh ALTTPGlbCa CTMRI MP Ca VAD QOL VAD MP MP VAD MP VAD kg PCV.;RPI.WBC,/l ALT IU/l TP. g/dlglb. g/dl Ca. mg/dl X X A CT MRI CT BCT MRI T T GdhDTPAT T ChF h h hh FAX hh E-mail : sayochan@vet.osakafu-u.ac.jp
More informationNew Questions About Transplantation in Multiple Myeloma
Review Article [1] September 01, 2006 By Parameswaran Hari, MD, MRCP [2], Marcelo C. Pasquini [3], and David H. Vesole, MD, PhD [4] Multiple myeloma is now the most common indication for autologous stem
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationSCIENTIFIC DISCUSSION
Product name: VELCADE Procedure No. EMEA/H/C/539/II/05 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel:(44-20) 74 18 84, fax (44-20) 74 18 86 68 E-mail: mail@emea.eu.int,
More information